Profile
Harvey N.
Masonson held several positions in the pharmaceutical industry, including Assistant Director-Clinical Safety at Bristol Myers Squibb Co., Director-Clinical Research at Sanofi-Synthelabo, Inc., Vice President-Clinical Development & Drug Safety at (OSI).
Eyetech, and Senior Vice President-Clinical Development at IVERIC bio, Inc. He also served as Vice President-Clinical Development at Gensight Biologics SA from 2018 to 2019.
Masonson earned a doctorate degree from the Icahn School of Medicine at Mount Sinai.
Former positions of Harvey N. Masonson
| Companies | Position | End |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Chief Tech/Sci/R&D Officer | 2018-12-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Corporate Officer/Principal | - |
| Sanofi-Synthelabo, Inc. | Chief Tech/Sci/R&D Officer | - |
| IVERIC BIO, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Harvey N. Masonson
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Private companies | 3 |
|---|---|
(OSI) Eyetech
(OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
| Sanofi-Synthelabo, Inc. | Health Technology |
- Stock Market
- Insiders
- Harvey N. Masonson
